The FDA approval of two anti-CD20 antibodies-ofatumumab and, recently, obinotuzumab-has greatly advanced the outlook for managing chronic lymphocytic leukemia.

Related Content:

PublicationsAugust 2011

Dr. Heymach on the Efficacy of Mobocertinib in EGFR Exon 20 Insertion–Mutated NSCLC

Practices Grapple With an Aging Oncology Workforce

Findings Suggest Cholesterol Plays a Surprising Role in Pancreatic Cancer